García-Frade RLF

Language: Spanish
References: 8
Page: 426-435
PDF size: 498.45 Kb.

ABSTRACT

The always worrisome balance between thrombosis and bleeding in the patient under the effect of an anticoagulant increases by the need of an invasive procedure, resulting in complex algorithms analyzed in this written in order to propose practical protocols that facilitate us to acquire reasoned knowledge of the perioperative management of the patient receiving anticoagulant therapy. If surgery is needed on a patient under anticoagulant therapy the following steps are suggested: establishing a real risk of thrombosis based on the procedure to be performed and hypercoagulable patient characteristics, establishing the risk of bleeding in relation to the procedure and the anticoagulant given to the patient, knowing the pharmacokinetics of anticoagulant in relation to the degree of renal function, establishing the need for a “bridge therapy” and its exact start and retreat in relation to certain variables and postoperative resumption of oral anticoagulant. Every one of the above steps is discussed in this article.

REFERENCES

1. Spyropoulos A, Douketis J. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120:2954-2962.

2. Guyatt G, Akl E, Crowther M, et al. Antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:7S-47S.

3. García-Frade LF. Tromboprofilaxis. En: Tratado de trombosis. García-Frade LF, editor. México: Alfil, 2015.

4. Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1131-1159.

5. Eriksson B, Dahl O, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, doubleblind, noninferiority trial. Lancet 2007;370:949-956.

6. Eriksson B, Dahl O, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185.

7. García-Frade LF, Solís E. Los nuevos anticoagulantes orales: una realidad. Med Int Mex 2013;29.

8. Schiele F, van Ryn J, Canada K, Newsome C, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554-3562.